AegirBio appoints new CEO
AegirBio AB (publ) announces that Marco Witteveen has been appointed as the new CEO, effective 15 June 2023.
Marco Witteveen has a degree within International Business from HU University of Applied Sciences Utrecht, an MBA within Sales Management and an MBA within Strategic Marketing. Marco Witteveen has previously had multiple different roles in Med Tech and diagnostic companies, respectively, including inter alia Vice President in NanoDx Inc with responsibility for the commercial strategy and its implementation for the company’s point-of-care in-vitro diagnostic products, Director for Werfen’s Benelux division where he managed the sales and marketing of the company’s products within point-of-care diagnostics, and multiple management roles at Alere Inc. Marco Witteveen is founder and CEO of Medestex.
The company’s current CEO, Bradley Messmer, will during a transfer period support Marco Witteveen in his new role. Bradley Messmer will also remain available as scientific adviser to AegirBio.
“I have worked with the board as a business consultant for the last month as part of the plans for the course going forward. The opportunity to be part of finalizing and implementing this plan was not a hard decision to make. This company rests on solid and interesting technologies and I am glad that Brad will be available with his scientific expertise to support this”, says Marco Witteveen.
“I am very happy to welcome Marco to AegirBio and look forward to supporting his efforts to lead the company to a bright future. We have navigated challenging waters over the past 15 months and I’m excited to see where a seasoned business professional can take this organization.”, says Bradley Messmer CEO AegirBio
This disclosure contains information that AegirBio is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-05-2023 18:03 CET.
For additional information please contact:
Anders Ingvarsson, CoB Aegirbio AB
Epost: [email protected]
Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.
The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs and suboptimal clinical outcomes.
The Company's tests for optimal dosing of biological drugs will be focused on neurological disorders, autoimmune diseases and cancer. Diagnostics will be offered through laboratory testing as well as in the form of a P.O.C. (Point of Care) test for use in hospitals and health centres. The plan further includes P.O.N. (Point of Need) tests for use at home.
For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | [email protected]
Integrum attends international expert workshop on osseointegration and bionic limb reconstruction
Mölndal, Sweden, September 27, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company is attending an international meeting and workshop event gathering experts in the field of osseointegration and bionic limb reconstruction, at the prestigious Rizzoli Or...
Capital increase in Monsenso A/S as a result of warrants exercising of employees
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares entitle to dividends and other rights in the company from the time of registration of the capital increase. The new shares will be admitted to listing on Nasdaq First Nort...
Kapitalforhøjelse i Monsenso A/S som følge af udnyttelse af warrants for medarbejdere
De nyudstedte aktier er ordinære aktier uden særlige rettigheder og er frit omsættelige omsætningspapirer. De nye aktier giver ret til udbytte og andre rettigheder i selskabet fra tidspunktet for registrering af kapitalforhøjelsen. De nye aktier vil blive optaget til notering på Nasdaq First North G...
Selektope® ger världens största civila sjukhusfartyg fullständigt skydd mot påväxt av havstulpan trots nära två års sammanräknat stillaliggande i vatten med hög risk för påväxt.
I-Techs antifoulingsubstans Selektope har framgångsrikt stått inför sin tuffaste utmaning hittills, att skydda sjukhusfartyget Global Mercy från påväxt av havstulpan under dess långa perioder av stillaliggande i varma vatten med hög risk för påväxt av havstulpaner. Trots att fartyget sammantaget leg...